Cell Proliferation Kit Market: Current Analysis and Forecast (2022-2028)

Cell Proliferation Kit Market: Current Analysis and Forecast (2022-2028)

The cell proliferation kit market is expected to register a CAGR of approx. 7% over the period of 2022-2028. Cell replication, or the process of cell proliferation, is essential for maintaining the homeostasis of adult tissues by replacing dead cells with fresh ones. This process begins during embryogenesis. Abnormal cell proliferation is seen in a few disease conditions, such as cancer. So, in both in vitro and in vivo settings, cell proliferation assay kits gained popularity in the clinical diagnosis of various disease indications. These are used in research studies of cell activation, cytotoxicity assessment, and clinical trials to determine therapeutic efficacy. The growing demand for cell proliferation kits can be attributed to the rising numbers of patients with cancer and tumors across the globe. For instance, according to the World Health Organization, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. In 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States. Owing to the glaring statistics the rising prevalence of cancer leads to higher demand for cell proliferation kits across the globe and would contribute to the growth of the market in the forthcoming period as well. Furthermore, the cell proliferation kit market is anticipated to grow on account of the increasing number of early diagnostic procedures. In addition, the rise in government initiatives to control the healthcare burden and growing healthcare awareness among people drive market growth. However, some of the restraints in the market including the high cost of kits and lack of trained professionals are impeding the growth of this market all over the world.

• Based on the type, the cell proliferation kit market is segmented into fluorometric cell viability kits, colorimetric cell viability kits, bioluminescent cell viability kits, and others. The colorimetric cell viability kits segment accounted for a significant market share in 2020 and it is estimated that it will grow rapidly during the projected timeframe. This method for detecting cell viability is cost-effective and easy to retrieve throughout data. It is also anticipated that the widespread use of this technique to identify various cellular activities, such as DNA synthesis, metabolic activity, and ATP production, will spur the expansion of the future market segment.
• Based on the application, the market is fragmented into pharmaceutical and biotechnology companies, academic institutes and research laboratories, and others. The pharmaceutical and biotechnology companies segment grabbed a considerable market share and is expected to grow at a significant CAGR during the forecast period. Cell proliferation kits are used in academic institutions and research labs to identify cell damage by monitoring how the cells respond to various stimuli, such as hydrogen peroxide, antibiotics, etc.
• For a better understanding of the market adoption of the cell proliferation kit, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the cell proliferation kit industry owing to the growing number of new cancer cases like melanoma, urothelial carcinoma, lung cancer, and others each year in the region. Moreover, the presence of well-established healthcare facilities, growing advanced technologies, as well as rising healthcare spending boost the market growth in this region. For instance, according to the centers for Medicare & Medicaid services, U.S. healthcare spending grew 2.7% in 2021, reaching USD 4.3 trillion or USD 12,914 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 18.3%.
• Some of the major players operating in the market include Thermo Fisher Scientific Inc, Merck KGaA, GE Healthcare, PerkinElmer Inc, Bio-Rad Laboratories, Inc., Becton Dickinson and Co, Biotium, Agilent Technologies Inc, F. Hoffmann-La Roche AG, and Biological Industries, among others. Several M&As along with partnerships have been undertaken.